Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Natural Remedies

Nurses And Midwives Looking For Real Reforms, Australia
The Federal Secretary of the Australian Nursing Federation, Ged Kearney and the Assistant Federal Secretary, Lee Thomas will be available for comment on the Prime Minister"s address on the challenges of Health Reform and the release of the NHHRC report.
generic viagra online
Democratic Senators Discuss Protecting Children From The Dangers Of Smoking
Democratic Senators Dick Durbin, Chris Dodd, Jack Reed and Frank Lautenberg joined Matt Myers, President of the Campaign for Tobacco-Free Kids, at a press conference this morning to discuss the Family Smoking Prevention and Tobacco Control Act. The legislation will give the Food and Drug Administration legal authority to regulate the sale, distribution and advertising of cigarettes in order to stop tobacco companies from targeting children and misleading the public.
News of the day
Hunger Hormone Fired Up By Fatty Foods, Not Empty Stomach
New research led by the University of Cincinnati (UC) suggests that the hunger hormone ghrelin is activated by fats from the foods we eat - not those made in the body - in order to optimize nutrient metabolism and promote the storage of body fat.
Health Insurance

Pluristem Therapeutics Announces First Patient Enrollment In Phase I Clinical Trial For Treatment Of Peripheral Artery Disease With PLX-PAD

Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (DAX:PJT), a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for a variety of disorders, announced today that the first patient has been enrolled in a Phase I clinical trial of the Company"s allogeneic placental-derived adherent stromal cell product, termed PLX-PAD. PLX-PAD is being used in patients afflicted with critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD). The first patient was enrolled at the Franziskus-Krankenhaus Hospital, Berlin. The initiation of this study follows the recent approval of the Company"s Clinical Trial Application (CTA) to begin clinical trials with PLX-PAD by the Paul Ehrlich Institute (PEI), the German competent authority in the European Union. The Phase I study is designed to evaluate the safety of PLX-PAD in patients with CLI. A total of up to fifteen adults with the disease will be included in the trial which is being conducted at the Franziskus-Krankenhaus Hospital and Charitç© - Universitç¤tsmedizin Hospital, Berlin. Zami Aberman, Chairman, President and CEO of Pluristem stated, "We are proud to begin clinical trials with PLX-PAD, a cellular therapeutic product derived from the placenta, the organ intimately involved in the miracle of birth and a ubiquitous of adult stromal cells that are easily obtained without harm to the mother or baby. Additionally, our proprietary three-dimensional mass manufacturing technology allows us to grow cells significantly more efficiently and cost-effectively than cells grown via the labor intensive two-dimensional method which is the industry norm." Pluristem Therapeutics Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009